PectaSol Modified Citrus Pectin Powder Super-Nutrient to Support Cellular & Immune Health, Joint Support - 454 Grams - Formulated by Dr. Isaac Eliaz of ecoNugenics

Product Information

As a dietary supplement, for maximum support, take 15 grams per day (3 scoops) in 2-3 divided doses, mixed with liquid, on an empty stomach. For maintenance support, take 1 scoop per day, mixed with liquid, on an empty stomach, or as recommended by your healthcare practitioner. PectaSol® Metal Detox provides clinically proven, natural detoxification to helplower body burden of heavy metals and environmental toxins such as radioactive particles. PectaSol® Metal Detox combines the detoxification properties of PectaSol-C® Modified Citrus Pectin and Algimate®, modified alginates purified from kelp seaweed, to bind to heavy metals in the digestive and circulation systems without disrupting essential mineral balance, for safe elimination.* George T, Brady MF. Ethylenediaminetetraacetic Acid (EDTA). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 33351441.

Plant-derived polysaccharides have also been proposed as therapeutics for liver, kidney and lung fibrosis, mainly via mechanisms that involve inhibition of GAL3 (refs. 142, 146). Inhibition of GAL3 with belapectin ( 18, Fig. 4) and Davanat ( 19, Fig. 4) was first evaluated in a toxin-induced model of liver fibrosis 232. Intraperitoneal administration of these polysaccharides resulted in decreased collagen content, attenuated liver fibrosis, diminished cirrhosis and a reduced percentage of GAL3-expressing macrophages 232. These two inhibitors were also tested in a murine model of NASH 233. Intravenous administration of belapectin resulted in a substantial reduction in collagen deposition, hepatocellular damage, NASH activity and fibrosis — features that were associated with reduced markers of inflammation that included inducible nitric oxide synthase (iNOS) and CD36 + pro-inflammatory macrophages. By contrast, administration of Davanat had no effect 233. A phase I clinical trial of belapectin ( 18) in patients with NASH with advanced hepatic fibrosis revealed no toxicity and good tolerability 234 (NCT01899859, Table 1). Two phase II clinical trials evaluated the efficacy of this compound in liver fibrosis. In patients with NASH with advanced fibrosis (NCT02421094, Table 1), belapectin had no significant effects on levels of non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period 234. In liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis 235 (NCT02462967, Table 1), belapectin had no impact on fibrosis or nonalcoholic fatty liver disease activity score. However, in a patient subgroup it showed a significant effect on portal pressure and prevented the development of oesophageal varices, which is an early sign of serious complications in patients with cirrhosis. This led to the development of a phase IIb/III trial designed to evaluate its safety and efficacy specifically in patients with NASH-associated cirrhosis for the prevention of oesophageal varices (NCT04365868, Table 1). Knopp RH, Superko HR, Davidson M, Insull W, Dujovne CA, Kwiterovich PO, et al. Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med. 1999 Jul;17(1):18–23. DOI: 10.1016/s0749-3797(99)00039-2. PMID: 10429748. While research is preliminary, modified citrus pectin has the potential to offer benefits for heart disease, cancer, IBS, and even cognition. It may also act as a natural chelating agent, helping individuals to safely detoxify from heavy metals. Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytother Res. 2006 Oct;20(10):859–64. DOI: 10.1002/ptr.1953. PMID: 16835878.

You may also like…

Sun H, Jiang H, Eliaz A, Kellum JA, Peng Z, Eliaz I. Galectin-3 in septic acute kidney injury: a translational study. Crit Care. 2021 Mar 18;25(1):109. DOI: 10.1186/s13054-021-03538-0. PMID: 33736691. PMCID: PMC7977587. More recently, OTX008 (or 0118, also called PTX008; 24, Fig. 5) was developed as a non-peptidic calixarene-based Anginex topomimetic with GAL1 binding capacity 248. OTX008 inhibited angiogenesis in both in vitro and mouse model systems 99, 249. It also synergized with the tyrosine kinase inhibitor sunitinib in ovarian carcinoma and glioblastoma xenograft models 250. A phase I clinical trial sponsored by Oncoethix assessed the impact of OTX008 administered subcutaneously to patients with advanced solid tumours and documented its rapid absorption and urinary excretion (NCT01724320) 251. More recently, Leung et al. 252 demonstrated that OTX008 combined with sorafenib reduced tumour growth and enhanced the therapeutic effects of sorafenib alone in experimental models of hepatocellular carcinoma. OTX008 was also effective against thyroid cancer in in vitro and in vivo studies 253. Other calixarene derivatives include the polycationic calixarene-based compound PTX013 ( 25), which displayed 50-fold enhanced activity over that of OTX008 in an experimental melanoma model 254. Furthermore, new analogues showed increased cell growth inhibitory activity in HUVECs and MA148 ovarian cancer cells, when compared with the parent calixarene compound 24 (ref. 255). However, the quest for improved activity led to ‘off-target’ side effects: PTX013 was toxic in mice, and considering that, in vitro, PTX013 could be considered a cytotoxic drug more than a cytostatic agent (like parental PTX008), the authors postulated that GAL1 might not be the only target of this compound 254, 256. In this sense, PTX013 has recently been shown to bind to both GAL3 and GAL1; this was suggested as a potential mechanism underlying its increased activity 257. The development of PTX013 is an important example of how structural modifications aimed at improving biological activity can result in increased toxicity via potentially different mechanisms of action 254. H. Dresler, et al., “Effect of PectaSol-C Modified Citrus Pectin (P-MCP) Treatment (tx) on PSA Dynamics in Non-Metastatic Biochemically Relapsed Prostate Cancer (BRPC) Patients (pts): Results of a Prospective Phase II Study,” Eur. Urol Suppl. 17(14): e2849 (2018).

This MCP is also shown to increase the effectiveness of radiotherapy and to synergise with two polybotanical anticancer formulas for breast and prostate cancer. 15,16 MCP in combination with a purified botanical extract from magnolia bark, honokiol (protected by US Patent No. 8916541 and European Patent EP2661173B1), has also shown synergy for antioxidant and anti-inflammatory effects. 17 Another randomized control trial concluded that at least 6 grams a day of pectin benefited cholesterol levels [ 6]. This trial also showed that citrus pectin was more effective than pectin derived from apples. L. Calvier, et al., “The Impact of Galectin-3 Inhibition on Aldosterone-Induced Cardiac and Renal Injuries,” JACC Heart Fail. 3(1), 59–67 (2015).In a 2011 study, MCP was shown to be a potent immune system booster. It had a powerful effect boosting B-lymphocytes, and also the cytoxic effects of T-lymphocytes and Natural Killer (NK) cells against cancer. MCP actually produced a dramatic 10-fold increase in NK cell activity (7) .